Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings (NASDAQ: ESTA) announced the publication of a study in Plastic and Reconstructive Surgery-Global Open, revealing that hybrid breast reconstruction using Motiva Ergonomix implants enhances outcomes compared to traditional methods. Analyzing 56 reconstructions in 33 patients, the findings highlighted improved control of breast shape and reduced complication risks. CEO Juan José Chacón-Quirós emphasized the commitment to innovative technology for better patient outcomes. It's important to note that these implants are not yet approved for commercial distribution in the U.S.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 2:00 PM ET. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will represent the company. The event will be available via live webcast on the Establishment Labs investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women's health, focusing on breast aesthetics and reconstruction, and offers products like Motiva Implants®, available in over 80 countries.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) will announce its financial results for Q2 2020 on August 6, 2020, post-market. A conference call is scheduled for 5:30 PM ET to discuss these results. The company focuses on women's health, particularly in breast aesthetics and reconstruction, with a product range including the Motiva Implants® and the Divina® 3D Simulation System. Motiva Implants® have received FDA approval and are available in over 80 countries through various distribution channels.